Biomedical subjects

P S Eriksson

Publications and source records attributed to P S Eriksson.

14 recordsLinked to original sources

PubMed1992

Volume regulation of single astroglial cells in primary culture.

Relative volume variations in cultured astrocytes were examined by microspectrofluorimetry after loading the cells with the highly fluorescent intracellular probes 2,7-bis(carboxyethyl)-5,6-carboxyfluorescein (BCECF/AM) or fura-2/AM. At their isosbestic points, 450 nm and 358 nm, respectively, the probes were ion-insensitive and the fluorescent signals emitted related only to the intracellular dye concentration. By varying the excitation wavelengths, changes in intracellular pH or Ca2+ transients could be recorded simultaneously with the relative volume variations of the individual cells. After exposure to a hypotonic buffer, type 1 astrocytes swelled within 30 s and subsequently underwent regulatory volume decrease (RVD). When exposed to a hypertonic buffer, the astrocytes shrunk and exhibited regulatory volume increase (RVI). One mM glutamate induced an increase in astrocyte volume in 60 sec and evoked cytosolic Ca2+ transients but did not change intracellular pH.

Animals↗

PubMed1992

Chronic elevation of cAMP levels induces changes in the adenylate cyclase system, opiate receptor sensitivity and levels of Gs-mRNA in cultured neurons.

Neurons in primary culture were treated (5 days) with the adenylate cyclase stimulator 10(-5) M forskolin. The basal adenylate cyclase was decreased by 57%. The acute stimulatory effect of forskolin was down-regulated by 48%. The inhibitory effects of the 3 opiate receptor agonists (mu, delta and kappa) were partly abolished. The abundance of mRNA encoding the stimulatory G-protein (Gs) was decreased prominently. The data indicate that the cAMP system in neuronal cells in primary culture is under dynamic regulation, possibly including altered Gs-protein gene expression. Furthermore, long-term forskolin treatment might induce increased proliferation in susceptible neural blast cells.

Adenylyl Cyclases↗

PubMed1992

Distribution of IGF-I mRNA and IGF-I binding sites in the rat kidney.

In the present study we have investigated the distribution of IGF-I mRNA and IGF-I binding sites in the rat kidney. The distribution of IGF-I mRNA was investigated using a simple and sensitive non-radioactive in situ hybridisation technique based on probe labelling with digoxigenin labelled-UTP followed by detection with conventional immunocytochemical techniques. IGF-I mRNA was found predominantly in medullary collecting ducts and sparsely in cortical collecting duct cells. In addition IGF-I mRNA was expressed in scattered proximal tubular cells in the cortex and in cells confined to the glomerular tuft. IGF-I binding sites were studied using radiolabelled IGF-I and conventional autoradiographical techniques on tissue sections. It was found that IGF-I binding sites were widely distributed throughout the entire kidney and that the specific binding was highest in the inner medulla. These findings add further complexity to the understanding of IGF-I production and action on renal structures.

Animals↗

PubMed1992

Delta and kappa opiate receptors in primary astroglial cultures. Part II: Receptor sets in cultures from various brain regions and interactions with beta-receptor activated cyclic AMP.

In a previous paper, delta and kappa opiate receptors were shown to be co-localized on the same cell in enriched primary cultures of astroglia from neonatal rat cerebral cortex. Activation of the receptors inhibited adenylate cyclase. In this work, the presence of opiate receptors was investigated in astroglial primary cultures from neonatal rat striatum and brain stem. Cyclic adenosine 3',5'-monophosphate accumulation was quantified in the presence of different opioid receptor ligands after stimulation of the cyclic adenosine 3',5'-monophosphate system with forskolin. Morphine was used as a mu receptor agonist. [D-Ala2, D-Leu5]-enkephalin or [D-Pen2, D-Pen5]-enkephalin were used as delta receptor agonists and dynorphin 1-13 or U-50,488H were used as kappa receptor agonists. Specific antagonists for the respective receptors were used. After striatum or brain stem cultures had been incubated in 10(-9)-10(-5) M of each [D-Ala2, D-Leu5]-enkephalin, [D-Pen2, D-Pen5]-enkephalin and Dynorphin 1-13 or U-50,488H, dose related inhibitions of the 10(-5) M forskolin stimulated cyclic adenosine 3',5'-monophosphate accumulation were observed. The changes were reversed to the forskolin-induced control level in the presence of the respective antagonists. 10(-9)-10(-5) M morphine did not significantly change the forskolin-induced accumulation of cyclic adenosine 3',5'-monophosphate in the cultures studied. Furthermore, cultures from cerebral cortex, striatum or brain stem were incubated with isoproterenol alone or together with morphine or [D-Ala2, D-Leu5]-enkephalin.(ABSTRACT TRUNCATED AT 250 WORDS)

3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cycloh↗

PubMed1992

Altered amounts of G-protein mRNA and cAMP accumulation after long-term opioid receptor stimulation of neurons in primary culture from the rat cerebral cortex.

Primary neuronal enriched cultures were incubated with mu (morphine, 10(-5) M), delta (DPDPE, 10(-6) M) and kappa (U-50,488H, 10(-5) M) receptor agonists for 5 days, respectively. Thereafter the acute inhibitory actions of mu, delta or kappa receptor agonists on forskolin stimulated cAMP accumulation was assayed. The effect of long term opioid treatment on the steady-state level of G-protein mRNA (G alpha s, G alpha i-1 and G alpha i-2) was analyzed using an RNAase protection hybridization assay. Incubation for 5 days with kappa receptor agonist resulted in an attenuated ability to decrease the accumulation of cAMP by kappa receptors, as well as mu and delta receptors, which was also observed after 5 days of incubation with the delta receptor agonist. Furthermore, the adenylate cyclase responsiveness to forskolin stimulation was markedly reduced in cultures treated with either delta or kappa receptor agonists. Five days of incubation with kappa receptor agonist resulted in an increase in the levels of G alpha s and G alpha i-2 mRNAs. No effects on the amounts of G alpha s mRNA, G alpha i-1 mRNA or G alpha i-2 mRNA were detected after 5 days of delta receptor stimulation. On the other hand, 5 days of mu receptor stimulation decreased the amounts of G alpha s, G alpha i-1 and G alpha i-2 mRNA. Incubation with kappa receptor agonist for 24 h resulted in a significant decrease in the forskolin-stimulated accumulation of cAMP. The stimulatory effect of forskolin was further decreased after 3 days incubation with kappa receptor agonist.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

PubMed1992

Regulation of G-PROTEIN mRNA abundancy and cAMP accumulation after long-term opioid incubation in primary cultures of astroglia from the rat cerebral cortex.

Primary astroglial cultures were incubated with delta (10(-6) M DPDPE) or kappa (10(-5) M U-50,488H) receptor agonists for 5 days. Thereafter, the acute inhibitory actions of delta or kappa receptor agonists on forskolin stimulated cAMP accumulation were assayed. The G alpha s, G alpha i-1 and G alpha i-2 mRNA levels were quantified after 5 days of either delta or kappa receptor agonist treatment using a solution hybridization, RNase protection assay. Pronounced effects were observed after 5 days of kappa receptor agonist [10(-5) M U-50,488H] incubation. This treatment resulted in an attenuation in the acute inhibitory action of delta and kappa receptor agonists. Furthermore, a decreased stimulatory action of forskolin was seen. Similar effects were also seen after delta receptor stimulation. We also investigated the effects after 24 h and 3 days of incubation with the kappa receptor agonist (10(-5) M) U-50,488H. The 24 h incubation resulted in a decreased sensitivity to the acute inhibitory action of delta and kappa receptor agonists in the astroglial cultures. This effect was further accentuated after the 3 days of incubation with 10(-5) M U-50,488H. No significant change was seen in the basal accumulation of cAMP after incubation with the kappa agonist U-50,488H. However, after 5 days of incubation with the delta agonist DPDPE, a significantly increased basal accumulation of cAMP was seen in the astroglial cultures. After 5 days of delta or kappa agonist incubation, an increase in G alpha s mRNA level and a decrease in G alpha i-2 mRNA level was seen compared with controls. No statistically significant alterations in the amount of G alpha i-1 mRNA were seen. The data obtained in the present study indicate that the effects of long-term opioid treatment alters the sensitivity of glial cell opioid receptors. Furthermore, long term opioid treatment induces alterations in glial G-protein mRNA levels.

3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cycloh↗

PubMed1991

The presence of glutathione in primary neuronal and astroglial cultures from rat cerebral cortex and brain stem.

The concentration of the tripeptide glutathione (GSH) was measured in primary cultures of neurons and astroglial cells from rat cerebral cortex and brain stem. The concentration of GSH was found to be approximately 20 nmol/mg protein in the neuronal culture from the cerebral cortex and ca. 40 nmol/mg protein in the neuronal brain stem cultures. A GSH concentration of approximately 20 nmol/mg was observed in the astrocyte cultures from both brain regions. The possibility to increase the GSH concentration was tested by incubating the cultures in the presence of the GSH precursor gamma-glutamylcysteine (gamma-GC). In the cultured astrocytes gamma-GC produced a dose-dependent increase in GSH. A similar increase was observed in the neuronal cultures, but this effect failed to reach statistical significance.

Animals↗

PubMed1991

Mu and delta opiate receptors in neuronal and astroglial primary cultures from various regions of the brain--coupling with adenylate cyclase, localisation on the same neurones and association with dopamine (D1) receptor adenylate cyclase.

Primary cultures, enriched in neurones or astroglial cells, from three phylogenetically different regions of the brain of the rat, the cerebral cortex, the striatum and the brain stem, were used to investigate the presence of opiate receptors, coupled to adenylate cyclase. Morphine was used as a mu-receptor agonist and [D-Ala2, D-Leu5]-enkephalin (DADLE) was used as a delta-receptor agonist. In the neuronal cultures, both ligands inhibited the prostaglandin (PG)E1-stimulated intracellular accumulation of cyclic AMP dose-dependently, with the most prominent effects seen in the cultures of striatum and with DADLE being more potent than morphine. The opiate receptor antagonist, naloxone reversed the effects. Morphine and DADLE, added together, inhibited the PGE1-stimulated accumulation of cyclic AMP, less than the sum of the effects of each drug. Therefore, it might be that these opioid receptors are localized together on the same neurone. Striatal neurones contained dopamine receptors coupled to cyclic AMP, as second messenger. It was shown that the D1 (dopamine) receptor-stimulated activity of adenylate cyclase was inhibited by the mu and delta opioid receptor ligands. Thus, interactions at the level of adenylate cyclase seem to exist between D1, mu and delta opiate receptors. In the astroglial enriched cultures, DADLE inhibited the PGE1-induced accumulation of cyclic AMP, however, with a less prominent effect in the brain stem cultures.(ABSTRACT TRUNCATED AT 250 WORDS)

Adenylyl Cyclases↗

PubMed1990

Delta and kappa opiate receptors in primary astroglial cultures from rat cerebral cortex.

The effects of mu, delta, and kappa receptor-agonists on forskolin stimulated cyclic adenosine-3',5'-monophosphate (cAMP) formation were examined in astroglial enriched primary cultures from the cerebral cortex of newborn rats. Intracellular cAMP accumulation was quantified by radioimmunoassay. Morphine was used as a mu-receptor agonist, D-Ala-D-Leu-Enkephalin (DADLE) as a delta-receptor agonist and dynorphin 1-13 (Dyn) as a kappa-receptor agonist. Basal cAMP levels were unaffected by either the opiate agonists or the antagonists used. In the presence of the cAMP stimulator forskolin, morphine had no significant effect on the cytoplasmic cAMP levels. DADLE caused a dose related inhibition of the forskolin stimulated cAMP accumulation. The effects of this delta receptor stimulation was blocked with the selective antagonist ICI 174.864. In the presence of Dyn, the forskolin stimulated cAMP accumulation was inhibited in a dose related manner. This kappa receptor stimulation was blocked with the selective antagonist MR 2266. Co-administration of DADLE and Dyn resulted in a non additive inhibition of the forskolin stimulated accumulation of cAMP. These findings indicate that astroglial enriched cultures from the cerebral cortex of rats express delta and kappa-receptors co-localized on the same population of cells, and that these receptors are inhibitory coupled to adenylate cyclase.

Animals↗

PubMed1990

Opiate receptors in neuronal primary cultures.

The occurrence and characteristics of mu-, delta- and kappa-receptors were studied as effects of the respective agonists on forskolin-stimulated accumulation of cAMP in neuronal enriched primary cultures from the cerebral cortex of foetal rats. Morphine or [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAGO) were used as mu-receptor agonists. [D-Ala2,D-Leu5]-Enkephalin (DADLE) or [D-Pen2,D-Pen5]-enkephalin (DPDPE) were used as delta-receptor agonists and dynorphin 1-13 (Dyn) or U-50,488H were used as kappa-receptor agonists. In the presence of 10(-8)-10(-5) M morphine or 10(-8)-10(-5) M DAGO, there was a dose-related inhibition of the 10(-5) M forskolin-stimulated accumulation of cAMP. The inhibitory action of morphine or DAGO was reversed by naloxone. In the presence of 10(-9)-10(-6) M DADLE or 10(-9)-10(-6) M DPDPE, there was also a dose-related inhibition of the forskolin-stimulated accumulation of cAMP and a similar result was obtained in the presence of 10(-9)-10(-5) M Dyn or 10(-9)-10(-5) M U-50,488 H. These findings indicate that neurones from the cerebral cortex in culture express mu-, delta- and kappa-receptors, that inhibit the forskolin-stimulated accumulation of cAMP. Administration of 10(-5) M morphine and 10(-6) M DADLE or 10(-6) M DPDPE together, resulted in a non-additive inhibition of the forskolin-stimulated accumulation of cAMP, indicating the presence of both mu- and delta-receptors on the same population of cells.

Animals↗

PubMed1989

A method for computer control of morphine ingestion by rats.

In this paper, we describe a method for controlling the administration of liquid diet and morphine to sixteen rats using a computer. Morphine ingestion treatment was performed with 6 feeding occasions per 24 hr, all experimental animals receiving similar drug doses. The amount of drug was individual and based on body weight at each feeding occasion. Control and experimental animals were kept under isocaloric conditions. Corrections of drug doses in order to compensate for changes in body weight were made every 24 hr. Sensors registered the exact time of complete drug and diet consumption and prevented overdistribution. Rats were administered 103 mg/kg b.wt. morphine during 24 hr. In another experiment rats were administered 191 mg/kg b.wt. morphine during 48 hr, and no weight loss or decrease in fluid diet intake was registered during the time of drug administration in either of the experiments. After exclusion of morphine from the fluid diet, the body weight loss was 6.1% and 8.3%, respectively, and the liquid diet intake decreased by 12.4 ml and 13.4 ml, respectively, compared with control animal intake. This demonstrates the induction of physical drug dependence. A major advantage of using computer-aided administration of morphine-admixed, fluid diet is the stepwise, small dose increments provided several times a day, resulting in higher drug dose per unit time when compared with ingestion procedures using one feeding occasion per day. The method enables rats to rapidly ingest large morphine doses under standardized conditions.

Animals↗

PubMed1989

Do persistent morphine effects involve interactions with the genome?

Male rats were administered morphine in a liquid diet until five days prior to mating with drug naive nulliparous female rats which received no treatment during gestation. The birth weight of resulting litters was significantly reduced. The preconceptionally morphine-treated offspring showed a 34.8% +/- 17.1% mortality during the first 8 days compared with 0% in the control group and their weight gain profile was decreased as compared with controls. A persistent effect of paternally administered morphine was seen in 90-day-old male offspring. A possible way to further enlighten the underlying mechanisms is proposed.

Animals↗

PubMed1989

Effects of prenatal morphine treatment of rats on mortality, bodyweight and analgesic response in the offspring.

A method is presented for the maternal ingestion of morphine in rats in order to investigate morphine's prenatal effects. Effects on the offspring of the treatment throughout pregnancy were compared with effects of treatment during specific periods of the pregnancy. Morphine treatment (25 mg/kg per day) throughout pregnancy resulted in 0% survival of the offspring. Morphine treatment up to gestational day 21 resulted in 65.4 +/- 7.7% survival of the offspring, and up to gestational day 17 in 31.8 +/- 13% survival. Reduction in the neonatal birth weight was maximal in animals treated with 25 mg/kg of morphine per day from gestational day 4 throughout pregnancy. The analgesic effect of morphine in the offspring was tested with the hot plate method. Male offspring treated with morphine from gestational day 1 to day 17 showed an elevated thermal response after morphine injections on day 80-90 post partum. These findings indicate a long-lasting, post-partum alteration in that part of the opiate system involved in the perception of noxious stimuli.

Animals↗

PubMed1987

Aspects of abstinence after morphine ingestion.

Sprague-Dawley male rats were intoxicated with morphine, using an ingestion method where exposed and control rats received equivalent amounts of calories and nutrients. The degree of physical dependence on morphine was demonstrated by studying and quantifying abstinence symptoms after withdrawal or after administration of opiate antagonists. The aims of the study were (1) to further enlighten the specificity and validity of the intoxication method concerning physical dependence, and (2) to determine whether some of the abstinence signs might be of value to facilitate quantitation of the degree of physical dependence on morphine, with diet and fluid intake being maintained under control. Withdrawn rats showed a decreased fluid diet intake and a body weight loss, the latter partly due to anorexia. Other mild abstinence signs were irritation, tremor and some motor excitation. The body weight loss during the first day of morphine withdrawal was proportional to the accumulated drug dose (between 25 and 300 mg morphine PO/kg b.wt.). However, prolonged morphine treatment on one dose (340 mg/kg b.wt.) did not reinforce the body weight changes caused by morphine withdrawal. The succeeding weight gain some days after morphine withdrawal was not entirely dependent on the amount of fluid diet intake. Methadone was shown to partially block the decrease in diet intake and the weight loss seen during morphine withdrawal. The naloxone-precipitated withdrawal symptoms were motor excitation, cholinergic signs, body weight loss, diarrhoea and decreased diet intake. The weight loss 2 hr after naloxone administration to long-term intoxicated rats was proportional to the naloxone dose.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗